|
Aug 7
|
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
|
|
Jul 21
|
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
|
|
Jul 18
|
Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
|
|
Jun 30
|
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
|
|
Apr 24
|
Top Penny Stocks To Watch In April 2025
|
|
Mar 10
|
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
|